<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669812</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000593564</org_study_id>
    <secondary_id>CRUK-2005-003906-27</secondary_id>
    <secondary_id>CRUK-BRD/05/93</secondary_id>
    <nct_id>NCT00669812</nct_id>
  </id_info>
  <brief_title>High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma</brief_title>
  <official_title>A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a peripheral blood stem cell transplant stops the&#xD;
      growth of cancer cells by stopping them from dividing or by killing them. After treatment,&#xD;
      stem cells are collected from the patient's blood and stored. More chemotherapy is given to&#xD;
      prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the&#xD;
      patient to replace the blood-forming cells that were destroyed by the chemotherapy.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying high-dose chemotherapy given together with&#xD;
      peripheral blood stem cell transplant in treating patients with intestinal T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the efficacy and toxicity of intensive high-dose chemotherapy (alternating&#xD;
           I'VE regimen and intermediate-dose methotrexate) followed by autologous peripheral blood&#xD;
           stem cell transplantation for treatment of patients with intestinal T-cell lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the toxicity of the regimen in a large population of these patients.&#xD;
&#xD;
        -  To provide a coordinated approach to the treatment of these patients.&#xD;
&#xD;
        -  To register patients unfit for the protocol chemotherapy into the pathological part of&#xD;
           the study.&#xD;
&#xD;
      OUTLINE: This is a multicenter study&#xD;
&#xD;
        -  Chemotherapy: Patients receive CHOP chemotherapy comprising cyclophosphamide IV over 15&#xD;
           minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1. Patients also&#xD;
           receive oral prednisolone on days 1-5.&#xD;
&#xD;
      After recovering from CHOP chemotherapy, patients receive I'VE chemotherapy comprising&#xD;
      epirubicin hydrochloride IV on day 1 and etoposide IV over 2 hours and ifosfamide IV&#xD;
      continuously on days 21-23. Patients also receive methotrexate IV over 24 hours on day 21.&#xD;
      Treatment repeats every 28 days for 3 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
        -  Consolidation therapy: On day 77, stem cells are collected from patients if the marrow&#xD;
           is clear of disease. After completion of chemotherapy, patients in complete remission&#xD;
           receive carmustine IV on day 105, cytarabine IV and etoposide IV on days 106-109, and&#xD;
           melphalan IV on day 110. These patients undergo autologous peripheral blood stem cell&#xD;
           transplantation on day 112.&#xD;
&#xD;
      Prior to study treatment, patients undergo a biopsy of the gut to confirm diagnosis and a&#xD;
      blood sample is taken. Both blood and tissue samples may be used for further studies.&#xD;
&#xD;
      After recovery from treatment, patients are followed monthly for 4 months, then bimonthly for&#xD;
      1 year, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and&#xD;
      then annually thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at 1 year</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lymphoma</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Newly confirmed diagnosis of intestinal T-cell lymphoma/ enteropathy-type T-cell&#xD;
             lymphoma according to the following WHO classifications:&#xD;
&#xD;
               -  Usual phenotype CD3-, CD7-positive; CD5-, CD4-, CD8-negative; or CD30-positive&#xD;
&#xD;
          -  Complete surgical resection allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Unsupported neutrophils ≥ 1,500/mm^3 unless attributed to lymphomatous bone marrow&#xD;
             infiltration&#xD;
&#xD;
          -  Unsupported platelets ≥ 100,000/mm^3 unless attributed to lymphomatous bone marrow&#xD;
             infiltration&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2.5 times ULN&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥ 50%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 1 month after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Patients with any serious concomitant medical or psychiatric condition that would&#xD;
             preclude them tolerating the planned treatment should be entered into the registration&#xD;
             study only&#xD;
&#xD;
          -  No known hepatitis B, hepatitis C, or HIV positivity&#xD;
&#xD;
          -  No active uncontrolled cardiovascular disease&#xD;
&#xD;
          -  No abnormal EKG if there is a previous history of cardiac problems&#xD;
&#xD;
          -  No other severe impairment of cardiac function&#xD;
&#xD;
          -  No active malignancy within the past 5 years except cervical intraepithelial neoplasia&#xD;
             or localized skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior diagnostic or emergency surgical procedures allowed&#xD;
&#xD;
          -  More than 5 years since prior treatment for malignancy&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for treatment of lymphoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Lennard</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Lennard</last_name>
      <phone>44-191-282-4743</phone>
      <email>a.l.lennard@ncl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>April 30, 2008</study_first_submitted>
  <study_first_submitted_qc>April 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2008</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>small intestine lymphoma</keyword>
  <keyword>stage I adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

